Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | GCGR | P47871 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5888122 | 0.77 | NOTUM (0.39) | RAB9AALDH1A1NPC1TDO2SMN1; SMN2 | |
| SCHEMBL4022997 | 0.76 | MAPT (0.48) | RAB9AALDH1A1NPC1SMN1; SMN2NOTUM | |
| SCHEMBL5601525 | 0.76 | NOTUM (0.40) | RAB9AALDH1A1NPC1SMN1; SMN2NOTUM | |
| SCHEMBL3284404 | 0.71 | — | — | |
| SCHEMBL8618979 | 0.65 | MAPK14 (0.39) | RAB9AALDH1A1ALOX5NPC1MAPK14 | |
| SCHEMBL3904273 | 0.65 | RAB9A (0.38) | RAB9AALDH1A1ALOX5NPC1MAPK14 | |
| SCHEMBL12562793 | 0.64 | BCL2L1 (0.55) | RAB9ANPC1SMN1; SMN2NOTUMPOLB | |
| SCHEMBL10300262 | 0.64 | BCL2L1 (0.55) | RAB9ANPC1SMN1; SMN2NOTUMPOLB | |
| SCHEMBL10337645 | 0.64 | BCL2L1 (0.55) | RAB9ANPC1SMN1; SMN2NOTUMPOLB | |
| SCHEMBL6829472 | 0.62 | LMNA (0.65) | MAPK14MAPK10GCGRNOTUMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026335-B2 | Melanocortin receptor ligands | THE PROCTER & GAMBLE CO. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20050239835-A1 | Melanocortin receptor ligands | EBETINO FRANK H | 2005-10-27 | — | — | US | disclosed |
| US-20050171158-A1 | Melanocortin receptor ligands | EBETINO FRANK H (US) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171158-A1 | Melanocortin receptor ligands | MC1R, MC4R, MC5R | RAB9A 1304/4885ALDH1A1 1069/4885ALOX5 1608/4885 |
| US-20050239835-A1 | Melanocortin receptor ligands | MC1R, MC4R, MC3R | RAB9A 1262/4885ALDH1A1 1506/4885ALOX5 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.